Have a feature idea you'd love to see implemented?
Let us know!
HAE Haemonetics Corp
Price (delayed)
$72.575
Market cap
$3.71B
P/E Ratio
32.11
Dividend/share
N/A
EPS
$2.26
Enterprise value
$4.59B
Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of
Highlights
The company's quick ratio has surged by 64% QoQ and by 8% YoY
The price to earnings (P/E) is 43% lower than the 5-year quarterly average of 56.4 and 10% lower than the last 4 quarters average of 35.8
The equity has declined by 6% since the previous quarter but it is up by 4.7% year-on-year
The debt has soared by 60% year-on-year and by 51% since the previous quarter
HAE's net income is down by 16% year-on-year and by 2.3% since the previous quarter
Key stats
What are the main financial stats of HAE
Market
Valuations
Earnings
Shares outstanding
51.18M
Market cap
$3.71B
Enterprise value
$4.59B
Price to earnings (P/E)
32.11
Price to book (P/B)
4.08
Price to sales (P/S)
2.77
EV/EBIT
30.42
EV/EBITDA
18.06
EV/Sales
3.44
Revenue
$1.33B
EBIT
$150.98M
EBITDA
$254.3M
Free cash flow
$90.51M
Per share
Balance sheet
Liquidity
EPS
$2.26
Free cash flow per share
$1.78
Book value per share
$17.81
Revenue per share
$26.18
TBVPS
$28.12
Total assets
$2.54B
Total liabilities
$1.64B
Debt
$1.22B
Equity
$905.37M
Working capital
$718.5M
Debt to equity
1.35
Current ratio
3.76
Quick ratio
2.1
Net debt/EBITDA
3.46
Margins
Efficiency
Dividend
EBITDA margin
19.1%
Gross margin
52.4%
Net margin
8.6%
Operating margin
11.3%
Return on assets
5.1%
Return on equity
12.4%
Return on invested capital
9%
Return on capital employed
6.6%
Return on sales
11.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HAE stock price
How has the Haemonetics stock price performed over time
Intraday
-0.72%
1 week
-0.98%
1 month
-9.71%
1 year
-14.54%
YTD
-15.13%
QTD
-9.71%
Financial performance
How have Haemonetics's revenue and profit performed over time
Revenue
$1.33B
Gross profit
$699.21M
Operating income
$150.98M
Net income
$114.89M
Gross margin
52.4%
Net margin
8.6%
The operating margin has contracted by 23% YoY and by 10% from the previous quarter
The net margin is down by 23% year-on-year and by 4.4% since the previous quarter
HAE's net income is down by 16% year-on-year and by 2.3% since the previous quarter
The operating income is down by 16% year-on-year and by 8% since the previous quarter
Growth
What is Haemonetics's growth rate over time
Valuation
What is Haemonetics stock price valuation
P/E
32.11
P/B
4.08
P/S
2.77
EV/EBIT
30.42
EV/EBITDA
18.06
EV/Sales
3.44
The price to earnings (P/E) is 43% lower than the 5-year quarterly average of 56.4 and 10% lower than the last 4 quarters average of 35.8
The company's EPS fell by 16% YoY and by 2.6% QoQ
The price to book (P/B) is 29% lower than the 5-year quarterly average of 5.8 and 13% lower than the last 4 quarters average of 4.7
The equity has declined by 6% since the previous quarter but it is up by 4.7% year-on-year
The stock's P/S is 32% less than its 5-year quarterly average of 4.1 and 18% less than its last 4 quarters average of 3.4
The revenue rose by 9% YoY
Efficiency
How efficient is Haemonetics business performance
The company's return on assets fell by 28% YoY and by 9% QoQ
The company's return on invested capital fell by 27% YoY and by 17% QoQ
HAE's return on equity is down by 27% year-on-year and by 3.1% since the previous quarter
The company's return on sales fell by 23% YoY and by 10% QoQ
Dividends
What is HAE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HAE.
Financial health
How did Haemonetics financials performed over time
The total assets is 55% more than the total liabilities
The company's quick ratio has surged by 64% QoQ and by 8% YoY
The total liabilities has grown by 49% YoY and by 32% from the previous quarter
The debt is 35% greater than the equity
The debt to equity has soared by 61% from the previous quarter and by 53% YoY
The debt has soared by 60% year-on-year and by 51% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.